The ESCMID Global Congress 2025 concluded successfully in Vienna, Austria, bringing together global leaders in infectious disease research, diagnostics, and clinical microbiology. Held from April 11–15, this prestigious event served as a strategic platform for advancing global health solutions, with a strong focus on antimicrobial resistance (AMR), emerging infectious diseases, and precision molecular diagnostics.

In an era marked by increasing globalization and the escalating threat of pandemic-scale outbreaks, the spread of multi-drug-resistant (MDR) pathogens and highly virulent strains poses a growing challenge to public health and economic stability. The ESCMID Global Congress provides critical insights and actionable solutions to mitigate these challenges.

Hzymes Biotech: Empowering Global Health with Cutting-Edge Enzyme Technology
As a recognized leader in enzyme R&D and manufacturing for IVD and biopharmaceutical applications, Hzymes Biotech showcased its breakthrough innovations at ESCMID Global 2025. The company’s presence reinforced its mission to “innovate core biotechnologies to benefit life”, aligning with global efforts to enhance diagnostic accuracy, treatment efficacy, and disease prevention.

Hanhai leverages five proprietary enzyme engineering platforms, providing high-performance, application-specific enzyme raw materials. With ISO 13485 certification and successful DMF (Drug Master File) filing with the U.S. FDA, the company guarantees quality, compliance, and international competitiveness.

Key Highlights from Hzymes Biotech at ESCMID Global 2025
✅ Comprehensive mRNA Solutions
Hzymes unveiled its end-to-end mRNA enzyme solution, covering R&D, process development, and rigorous quality control. These solutions are engineered to accelerate mRNA vaccine and therapeutic pipelines, making them ideal for gene therapy, cancer immunotherapy, and personalized medicine.

✅ Next-Generation Nucleic Acid Detection Platforms
In the field of molecular diagnostics, Hanhai presented its latest advancements in nucleic acid extraction, real-time PCR (qPCR), and isothermal amplification (LAMP) technologies. The innovative one-step multiplex RT-qPCR system drew significant attention for its speed, precision, and scalability—catering to diverse application scenarios, from clinical diagnostics to veterinary medicine.

 Looking Ahead: Enabling a Healthier Future with Enzyme-Driven Biotech
Hzymes Biotech remains committed to expanding its technological frontier in synthetic biology, gene editing, and next-gen diagnostics. By fostering strategic partnerships and driving open innovation, the company aims to raise global standards in biotechnology and support the sustainable development of the life sciences ecosystem.

From rapid molecular testing platforms to scalable mRNA enzyme systems, Hanhai is not just keeping pace with the industry’s evolution—it is actively shaping its future.

Visit Hzymes Biotech’s official website to explore our full portfolio of high-performance enzyme solutions for IVD, molecular diagnostics, and biopharma applications.